Baron Lab

Research focus

NIH R01 · 2025

Immune analysis of the HBsAg seroclearance response terminating chronic HBV

PROJECT SUMMARY Chronic infection with hepatitis B virus (HBV) is a major global problem affecting an estimated 300 million people. HBV-induced immune-mediated progressive liver injury and primary liver cancer led to a WHO-estimated 820,000 deaths in 2019. While clearance of the HBV surface antigen (HBsAg) defines clinical cure and reduces all disease-associated risks, HBsAg clearance is rarely observed and remains therapeutically elusive. As such, there remains a clear and urgent need for finite therapies that safely induce HBsAg clearance, at least in a significant subset of CHB patients. Our mouse models of human HBV reliably mimic HBsAg clearance and persistence in humans. Our published…

From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.